IP Verse

Alnylam Pharmaceuticals patent opposition analysis

Get complete Patent Opposition Report for Alnylam Pharmaceuticals

Comprehensive Analysis, Strategic Insights & Expert Evaluation – Stay Ahead in Your Patent Challenge.

Download Your Report Now

Latest oppositions filed by Alnylam Pharmaceuticals

Explore patent oppositions filed by Alnylam Pharmaceuticals against competitors, revealing strategic technology disputes and market positioning. Monitor opposition details, timelines, and disputed innovations to understand competitive dynamics and IP enforcement strategy.

Patent NumberTitleApplicantOpposition Date
EP2978451Compositions And Methods For Increasing The Serum Half-Life Of A Therapeutic Agent Targeting Complement C5ALEXION PHARMACEUTICALSAug 27, 2020
EP3222724Further Novel Forms Of Interfering Rna MoleculesSILENCE THERAPEUTICSOct 31, 2018
EP1857547Further Novel Forms Of Interfering Rna MoleculesATUGENAug 17, 2018
EP2258847Futher Novel Forms Of Interfering Rna MoleculesSILENCE THERAPEUTICSOct 19, 2017

Latest patents of Alnylam Pharmaceuticals opposed by its competitors

Explore Alnylam Pharmaceuticals's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Patent NumberGrant DateTitleTotal Oppositions
EP3366775Apr 27, 2022Modified Rnai Agents1
EP3656860Apr 20, 2022Angiopoietin-Like 3 (Angptl3) Irna Compositions And Methods Of Use Thereof1
EP3105331Jun 23, 2021Ketohexokinase (Khk) Irna Compositions And Methods Of Use Thereof1
EP2723758Jun 20, 2018Angiopoietin-Like 3 (Angptl3) Irna Compostions And Methods Of Use Thereof2

Top competitors of Alnylam Pharmaceuticals